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Cancer cell-secreted IGF2 instigates ﬁbroblasts
and bone marrow-derived vascular progenitor cells
to promote cancer progression
Wen Wen Xu1,2,*,w, Bin Li1,2,3,*,w, Xin Yuan Guan3,4, Sookja K. Chung1, Yang Wang5, Yim Ling Yip1,
Simon Y.K. Law3,6, Kin Tak Chan3,6, Nikki P.Y. Lee3,6, Kwok Wah Chan3,7, Li Yan Xu8, En Min Li8, Sai Wah Tsao1,3,
Qing-Yu He5 & Annie L.M. Cheung1,2,3
Local interactions between cancer cells and stroma can produce systemic effects on distant
organs to govern cancer progression. Here we show that IGF2 secreted by inhibitor of
differentiation (Id1)-overexpressing oesophageal cancer cells instigates VEGFR1-positive bone
marrow cells in the tumour macroenvironment to form pre-metastatic niches at distant sites
by increasing VEGF secretion from cancer-associated ﬁbroblasts. Cancer cells are then
attracted to the metastatic site via the CXCL5/CXCR2 axis. Bone marrow cells transplanted
from nude mice bearing Id1-overexpressing oesophageal tumours enhance tumour growth
and metastasis in recipient mice, whereas systemic administration of VEGFR1 antibody
abrogates these effects. Mechanistically, IGF2 regulates VEGF in ﬁbroblasts via miR-29c in a
p53-dependent manner. Analysis of patient serum samples showed that concurrent elevation
of IGF2 and VEGF levels may serve as a prognostic biomarker for oesophageal cancer.
These ﬁndings suggest that the Id1/IGF2/VEGF/VEGFR1 cascade plays a critical role in
tumour-driven pathophysiological processes underlying cancer progression.
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C
ancer has been described as a systemic disease rather than
a local phenomenon1. Tumour cells not only interact
with the stroma in the local environment (tumour
microenvironment) but also connect with the body systems
(macroenvironment) via blood and lymphatic vessels2,3.
Fibroblasts are the most abundant cell type within the tumour
stroma of many cancers, and activation of ﬁbroblasts has been
reported to contribute to tumour growth4,5. In contrast to cancer
cells, stromal cells are more genetically stable and thus represent
an attractive target for cancer therapy. However, we are still far
from fully understanding the complex crosstalk between cancer
cells and stroma.
Metastasis is an important process that allows cancer cells to
escape from the primary tumour and settle in distant organs.
Metastatic cancers are largely incurable and are estimated to
account for 90% of mortality from cancer6. Although recent
studies have shed light on some of the mechanisms of metastasis,
the molecular components that mediate the engraftment of
tumour cells at these sites have yet to be fully identiﬁed.
Tumour growth at both primary and secondary sites requires
neovascularization and angiogenesis7. Prognosis of patients with
esophageal squamous cell carcinoma (ESCC) is correlated with
tumour vascularity8. The signiﬁcance of Id (inhibitor of
differentiation) proteins in supporting tumour angiogenesis and
metastasis was documented in as early as 1999 (ref. 9).
Subsequently, upregulation of Id1 was found to be strongly
associated with, and functionally contributes to, the development
of human cancer10,11. Moreover, Id1 was reported to have
prognostic signiﬁcance in patients with ESCC12,13. Our previous
studies showed that Id1-overexpression induces ESCC cells to
produce and secrete insulin-like growth factor 2 (IGF2), which
stimulates cancer cell proliferation in an autocrine manner14,
and that concurrent high Id1 and IGF2 expression in ESCC is
associated with shorter survival15. In the present study, we
examined whether Id1-induced IGF2 plays any role in tumour
angiogenesis and whether it exerts paracrine effects in the tumour
microenvironment and tumour macroenvironment to further
facilitate cancer progression. We also investigated the cellular
crosstalk and molecular signalling in the tumour micro- and
macroenvironment in order to obtain a better understanding of
cancer progression that may facilitate development of novel
systemic therapy. Our results show that IGF2 secreted by
Id1-expressing cancer cells not only activates the tumour
microenvironment by inducing ﬁbroblasts to secrete vascular
endothelial growth factor (VEGF), but this mechanism also
instigates the tumour macroenvironment so that bone marrow
cells primed by the presence of Id1-expressing tumours can
facilitate tumour growth and distant metastatic colonization.
These effects can be abolished by systemic administration of
VEGFR1 antibody. Furthermore, we reveal that IGF2 regulates
VEGF via miR-29c in a p53-dependent manner. These data
suggest a critical role for the Id1/IGF2/VEGF/VEGFR cascade in
driving oesophageal cancer progression. Furthermore, our study
provides evidence to support the potential clinical application of
VEGFR1 antibody in the treatment of oesophageal cancer.
Results
Id1-induced IGF2 from ESCC cells activates ﬁbroblasts.
Vascular endothelial growth factor (VEGF)-dependent endothe-
lial cell sprouting is a main mechanism of tumour angiogenesis.
To investigate the role of Id1-induced IGF2 on VEGF-mediated
tumour angiogenesis, we ﬁrst compared the microvessel density
in subcutaneous tumour xenografts established from KYSE150-
Id1-shCON, KYSE150-Id1-shIGF2 and KYSE150-CON-shCON
ESCC cells. The results showed higher microvessel density in the
Id1-overexpressing tumour xenografts, compared with tumours
that expressed Id1-shIGF2 or control vectors (Fig. 1a). We found
that although serum concentration of human VEGF in the
nude mice was comparable among the three groups, remarkably
higher concentration of mouse VEGF was detected in the
KYSE150-Id1-shCON group, suggesting that the elevated VEGF
was host-derived and likely to be stimulated by Id1-induced IGF2
(Fig. 1b). These results were conﬁrmed using another ESCC cell
line, KYSE270 (Supplementary Fig. 1a,b). To determine whether
other Id genes could compensate for Id1 in this mechanism, we
used speciﬁc small interfering RNAs (siRNAs) to knock down
Id2, Id3 and Id4, respectively, in ESCC cells and found that
manipulating the expression of these Id genes had no effect on the
expression of IGF2, thus afﬁrming the speciﬁcity of Id1 in this
process (Supplementary Fig. 1c).
Next, we investigated the paracrine effect of cancer cell-
secreted IGF2 on ﬁbroblasts. Two normal oesophageal ﬁbroblast
(NEF) cell lines, designated NEF3 and NEF4 (established from
normal oesophageal tissue of patients who underwent surgical
resection of primary oesophageal tumour), which had conﬁrmed
ﬁbroblastic phenotype (Supplementary Fig. 1d), were used to test
the paracrine effects of ESCC cells on ﬁbroblasts. We found that
the conditioned medium collected from Id1-overexpressing ESCC
cells not only markedly induced NEFs to acquire
myoﬁbroblast phenotype characterized by alpha smooth muscle
actin (a-SMA) expression, but also stimulated the expression and
secretion of VEGF. However, addition of neutralizing antibody
against IGF2, or inhibition of IGF2 by shRNA knockdown, failed
to recapitulate these effects (Fig. 1c,d). To study whether other
angiogenic molecules might be important in this process, we
further analysed the ﬁbroblasts treated with conditioned medium
from Id1-overexpressing ESCC cells for expression of placental
growth factor and ﬁbroblast growth factor. However, we did not
observe any change in the expression level of these molecules
(Supplementary Fig. 1e).
To directly test whether IGF2 was the main driver of this effect,
NEFs were treated with recombinant human IGF2 (rhIGF2), and
the results showed a dose-dependent increase of ﬁbroblast VEGF
and a-SMA expressions (Fig. 1e), as well as VEGF secretion
(Fig. 1f). With respect to functional effects, we found that
treatment with conditioned medium from Id1-overexpressing
ESCC cells for 24 h induced the migration (Fig. 1g) but not the
proliferation (Supplementary Fig. 1f) of ﬁbroblasts, and that the
effect was attenuated by IGF2 knockdown in cancer cells,
or addition of IGF2-neutralizing antibody to the conditioned
medium. The direct involvement of IGF2 in these effects was
conﬁrmed by the data showing that rhIGF2 promoted the
migration of ﬁbroblasts (Fig. 1h) and that the effect was not
due to increased cell proliferation (Supplementary Fig. 1g).
Meanwhile, IGF2-activated ﬁbroblasts or ﬁbroblasts co-cultured
with Id1-overexpressing ESCC cells were found to exert
multifaceted effects on the local tumour microenvironment by
inducing the proliferation, migration and tube formation
(Supplementary Figs 2a–c and 3) of human umbilical vein
endothelial cells, as well as increasing the invasion of ESCC cells
(Supplementary Fig. 2d).
Taken together, the results provided the ﬁrst evidence showing
that Id1-induced IGF2 from cancer cells can activate stromal
ﬁbroblasts in a paracrine manner, and stimulate them to produce
VEGF as well as to adopt a more cancer-promoting phenotype.
Clinical relevance of serum IGF2 and VEGF expression levels.
Most studies of tumour VEGF expression do not make a dis-
tinction between cancer cells and the stroma. We investigated the
correlation between oesophageal tumour IGF2 expression and
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Figure 1 | Id1-induced IGF2 activates ﬁbroblasts in a paracrine manner. (a) Tumour xenografts established from KYSE150-CON-shCON,
KYSE150-Id1-shCON or KYSE150-Id1-shIGF2 ESCC cells were immunostained for CD31 and analysed for microvessel density (female 6–8-week-old nude
mice, n¼ 3 per group; scale bar, 100 mm). (b) Human VEGF (left panel) and mouse VEGF (right panel) concentration in serum of mice bearing
Id1-overexpressing, Id1-shIGF2 or control tumours (female 6–8-week-old nude mice, n¼ 6 per group) was analysed using ELISA. (c,d) Expression of
VEGF and a-SMA (c) and secretion of VEGF (d) in ﬁbroblasts fed with conditioned medium (CM) from KYSE150-CON-shCON, KYSE150-Id1-shCON or
KYSE150-Id1-shIGF2 cells were assayed using western blot and ELISA, respectively. (e,f) Expression of VEGF and a-SMA (e) and secretion of VEGF (f) in
ﬁbroblasts treated with recombinant human IGF2. (g,h) Chemotactic migration of ﬁbroblasts in response to conditioned medium (scale bar, 100 mm) from
indicated ESCC cells (g) and exogenous IGF2 (h).Three biological replicates were performed for in vitro assays. Data in bar charts are presented as
mean±s.d.; *Po0.05; **Po0.01; ***Po0.001 by Student’s t-test.
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ﬁbroblast VEGF expression by isolating cancer-associated ﬁbro-
blasts (CAFs) and NEFs from 11 cases of ESCC and adjacent
normal tissues, respectively. Western blot analysis showed that,
with the exception of case no. 7, IGF2 expression was elevated in
10/11 (90.9%) of the tumour samples compared with corre-
sponding tumour-adjacent normal tissue (Fig. 2a). Furthermore,
there was upregulation of VEGF (except cases no. 2 and 7) and
a-SMA (except case no. 2) in CAFs compared with NEFs in 81.8
and 90.9% of the cases, respectively (Fig. 2a). Statistical analysis
showed that IGF2 expression in oesophageal tissues was positively
correlated with VEGF and a-SMA expressions in the corre-
sponding ﬁbroblasts (Fig. 2b). We also analysed the association
between expression levels of Id1 in oesophageal tissues and
ﬁbroblast VEGF and found a positive correlation although a
statistical signiﬁcance could not be established (Supplementary
Fig. 4a).
To study the clinical relevance of circulating IGF2 and VEGF
in ESCC patients, serum IGF2 and VEGF levels in 100 ESCC
patients with survival data were determined using ELISA and
compared with that of 50 healthy individuals. The IGF2 and
VEGF concentrations were found to be higher in ESCC patients,
and were positively correlated with each other (Fig. 2c). More-
over, the patients with concomitant high IGF2 and VEGF
expression had shorter survival (median survival¼ 10.1 months)
than patients with low IGF2 and VEGF expression (median
survival¼ 22.3 months) (Fig. 2d). Concurrent elevation of serum
IGF2 and VEGF was associated with T3/T4 stages, distant
metastasis and advanced pathologic stages (Stages III/IV)
(Supplementary Table 1). Multivariate survival analyses showed
that combined elevated expression of serum IGF2 and VEGF was
an independent unfavourable prognostic indicator for ESCC
patients (Supplementary Table 2). In addition, by analysing a
dataset containing 53 patients with primary breast tumours in
Gene Expression Omnibus (GEO) database, we found a
correlation between stromal VEGF level and poor survival and
recurrence (Supplementary Fig. 4b).
miR-29c mediates regulation of IGF2 on VEGF in ﬁbroblasts.
To investigate the mechanisms by which IGF2 regulates VEGF in
ﬁbroblasts, we initiated a screening for candidate miRNAs, which
can potentially regulate VEGF expression. Three miRNA target
prediction software were utilized to search for the miRNAs that
may bind to the 30UTR of VEGF. Among the candidate miRNAs,
40 miRNAs with highest scores (Supplementary Table 3) were
selected and real-time RT-PCR was performed to further screen
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Figure 2 | Clinical relevance of tumour IGF2 and stromal VEGF axis. (a) Western blot showing expression of IGF2 in ESCC (T) and matched non-tumour
specimens (N), as well as expression of VEGF and a-SMA in CAFs and matched NEF from 11 ESCC patients. (b) Graphs showing positive correlation
between IGF2 expression in oesophageal tissue and expressions of VEGF (left panel) and a-SMA (right panel) in ﬁbroblasts, respectively, in 11 pairs of
ESCC and adjacent normal tissues. Correlation was assessed using Pearson’s rank correlation coefﬁcient. (c) Comparison of serum IGF2 (left panel) and
VEGF (middle panel) levels between healthy individuals (n¼ 50) and ESCC patients (n¼ 100); the data were pooled and a positive correlation was found
between serum VEGF and IGF2 levels (n¼ 150) (right panel) using unpaired t-test. (d) Gene expressions were further divided into high and low levels using
median expression level as the cut-off point for survival analyses. Kaplan–Meier curves comparing survival outcome of ESCC patients (n¼ 100) with
high and low serum IGF2 levels (left panel), high and low serum VEGF levels (middle panel), and IGF2 High/VEGF High and IGF2 Low/VEGF Low levels
(right panel); statistical signiﬁcance was calculated by log-rank test.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms14399
4 NATURE COMMUNICATIONS | 8:14399 | DOI: 10.1038/ncomms14399 | www.nature.com/naturecommunications
for miRNAs that were downregulated in the ﬁbroblasts after IGF2
treatment. This approach allowed us to narrow the list of
candidate miRNAs down to miR-127-5p and miR-29c, both of
which satisﬁed the criteria of having seed regions that perfectly
matched with the 30UTR of VEGF (Fig. 3a) and were
downregulated in ﬁbroblasts upon IGF2 treatment (Fig. 3b).
Western blot analysis showed that transfection with the plasmids
expressing miR-127-5p and miR-29c resulted in reduction of
VEGF expression in ﬁbroblasts (Fig. 3c). Interestingly, when we
overexpressed these miRNAs in ﬁbroblasts, genetic enforcement
of only miR-29c (Fig. 3d), but not miR-127-5p, abrogated the
upregulation of VEGF expression induced by IGF2, implying that
miR-29c may mediate the effect of IGF2 on VEGF. In the 11 pairs
of ESCC and adjacent normal tissues mentioned in the previous
section, miR-29c expression was lower in CAFs than in NEFs
(Fig. 3e, left panel), and was inversely correlated with IGF2
expression (Fig. 3e, right panel).
Next, gain- and loss-of-function experiments using miR-29c
mimic and inhibitor conﬁrmed the regulation of VEGF by
miR-29c in ﬁbroblasts (Fig. 3f). In the luciferase reporter assay,
overexpression of miR-29c led to a dose-dependent decrease in
VEGF 30UTR reporter expression (Fig. 3g, left panel), but there
was no repression of luciferase activity in the ﬁbroblasts
co-transfected with miR-29c and mutant VEGF 30UTR (Fig. 3g,
right panel), indicating that miR-29c directly binds to the 30UTR
of VEGF. At the functional level, Boyden chamber assay showed
that the enhanced migration of ﬁbroblasts induced by IGF2 could
be attenuated by overexpression of miR-29c (Fig. 3h). Taken
together, these data suggest that IGF2 induces the activation of
ﬁbroblasts to produce VEGF via the mediation of miR-29c.
Regulation of miR-29c by IGF2 is p53-dependent. The
mechanism by which IGF2 negatively regulates miR-29c expres-
sion was investigated. Results from TaqMan pri-miRNA assay
showed that the addition of rhIGF2 to ﬁbroblasts decreased the
expression of pri-miR-29c (Fig. 4a), the most upstream RNA
molecule in miR-29c biogenesis, which suggests that IGF2
regulates miR-29c at transcriptional level. By using in silico
prediction, three potential p53 binding sites were identiﬁed in the
promoter region of miR-29c, leading us to speculate that p53 may
participate in the regulation of miR-29c by IGF2.
Gain- and loss-of-function experiments demonstrated that p53
had a positive regulatory effect on the expression of miR-29c
(Fig. 4b). Western blot analysis showed that p53 negatively
regulated the expression of VEGF in ﬁbroblasts (Fig. 4c).
Chromatin immunoprecipitation-quantitative PCR assay was
performed to determine whether there is physical interaction
between p53 protein and the promoter region of miR-29c. Of the
three potential p53 binding sites in the promoter region of
miR-29c (designated as BS1, BS2, BS3), enrichment of BS3
fragment, but not BS1 or BS2, was observed when cells were
co-transfected with plasmids expressing p53 and wild type
miR-29c promoter (Fig. 4d). To further conﬁrm the direct
binding between p53 and the promoter of miR-29c, site-speciﬁc
mutations were performed and luciferase assay demonstrated that
only BS3, but not the others, functions as the p53-responsive
element (Fig. 4e). These results collectively suggest that p53 plays
a crucial role in mediating the regulation of IGF2 on the
expression of miR-29c by directly binding to the promoter of
miR-29c. The signiﬁcance of p53 in this regulatory mechanism
was further tested using p53-null mouse embryonic ﬁbroblasts
(p53 / MEFs). Unlike p53-expressing ﬁbroblasts that showed
dose-dependent increase in VEGF in response to IGF2
(Supplementary Fig. 1h), there was no change in miR-29c and
VEGF levels in p53 / MEFs upon IGF2 treatment (Fig. 4f).
Moreover, we found that while exogenous IGF2 decreased the
expression of p53 in normal oesophageal ﬁbroblasts, the
expressions of p-AKT and p-MDM2, which are upstream
regulators of p53, were increased (Supplementary Fig. 1h),
suggesting that IGF2 may regulate p53 expression through the
AKT/MDM2 pathway. Subsequent experiments showed that
overexpression of p53 in NEFs abolished the elevation of VEGF
induced by IGF2 (Fig. 4g). A schematic diagram depicting the
functions of p53 and miR-29c in the regulatory mechanism of
IGF2 on VEGF expression in ﬁbroblasts is given in Fig. 4h.
Id1-expressing tumour instigates VEGFR1þ bone marrow cells.
In view of the importance of bone marrow-derived cells
(BMDCs) in tumour progression16, we investigated whether
Id1-expressing tumour can mobilize and home BMDCs to
tumour and pre-metastatic sites. To establish a traceable
system, we transplanted the bone marrow of transgenic mice
expressing green ﬂuorescent protein (GFP) into groups of lethally
irradiated recipient nude mice (Fig. 5a). Different groups of
recipient mice were inoculated subcutaneously with human ESCC
(KYSE150) cells expressing Id1, Id1-shIGF2 and control vectors,
respectively, 2 weeks after bone marrow transplantation.
To identify and characterize the BMDC subpopulations that
were inﬂuenced by Id1-overexpressing tumour xenografts,
subpopulations of BMDCs that are known to contribute to
tumorigenesis5, identiﬁed by different cell-surface antigens
including CD11b, F4/80, CD335, Gr-1, Tie-2, VEGFR1 and
VEGFR2, were analysed. We found an enrichment of
GFPþ /VEGFR1þ cells (Fig. 5b and Supplementary Fig. 5a),
but not the other subpopulations (Supplementary Fig. 5b),
in the bone marrow of mice bearing Id1-expressing tumours,
compared with the Id1-shIGF2 and the vector control groups.
Flow cytometry analysis also showed similar enrichment of
GFPþ /VEGFR1þ bone marrow cells in the lungs (which is a
common site of ESCC metastasis) of the Id1 group (Fig. 5c and
Supplementary Fig. 5a). Five weeks after implantation of cancer
cells, an accumulation of GFPþ cells was detected in the tumour
xenografts and thoracic region using three-dimensional in vivo
mouse imaging (Fig. 5d, left panel). Flow cytometry analysis of
the tumour xenografts revealed an increase in GFPþ /VEGFR1þ
cells, but not the other subpopulations, in the Id1 group only
(Fig. 5d, right panel and Supplementary Fig. 5a). These results not
only conﬁrmed that VEGFR1þ BMDCs were recruited to the
‘primary’ tumour and secondary sites, but also suggested that
Id1-induced IGF2 plays an important role in activating and
mobilizing VEGFR1þ BMDCs.
Bone marrow cells collected from nude mice without prior
treatment were sorted into VEGFR1þ and VEGFR1
populations (Supplementary Fig. 6a). In vitro experiments
showed that VEGFR1þ bone marrow cells exhibited
higher migratory potential than VEGFR1 bone marrow cells
(Fig. 5e). Furthermore, exposure to conditioned medium from
IGF2-activated ﬁbroblasts could enhance the migratory potential
and proliferation of VEGFR1þ bone marrow cells, whereas the
presence of VEGF antibody attenuated such effects (Fig. 5f and
Supplementary Fig. 6b). The presence of VEGF antibody could
also abolish the enhanced migration of VEGFR1þ bone marrow
cells attracted by the co-culture of ﬁbroblasts with Id1-expressing
cancer cells (Supplementary Fig. 6c). The preponderance of
VEGFR1þ BMDCs in the growing tumours and the lungs of the
Id1 group prompted us to explore whether inhibiting the activity
of these cells by VEGFR1 inactivation could suppress tumour
growth and metastasis. Using the in vivo models described in
the previous paragraph, we found that VEGFR1 inactivation
by treatment with anti-mouse VEGFR1-speciﬁc neutralizing
antibody (MF-1) was as effective as IGF2-knockdown in retarding
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the rapid growth of Id1-shCON tumour (Fig. 5g) and
reducing the percentage of VEGFR1þ cells in tumour xenografts
(Supplementary Fig. 7). To determine if other VEGFR1þ
BMDC-enriched sites in the tumour macroenvironment (such
as the lungs) favoured metastasis, the subcutaneous tumours were
allowed to grow in vivo for 2 weeks to prime the tumour
macroenvironment. The tumours were then removed and
Luc-expressing KYSE150 cells were introduced intravenously
into the circulation for experimental metastasis assay. Biolumi-
nescent imaging showed that lung metastasis occurred most
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rapidly in the mice bearing Id1-expressing tumour, and that
treatment with MF-1 to inactivate host VEGFR1 substantially
reduced lung metastasis (Fig. 5h).
Taken together, these data showed that Id1-induced IGF2
from primary tumours can affect the tumour micro- and
macroenvironment by systemically activating and mobilizing
VEGFR1þ BMDCs to facilitate tumour growth and metastasis.
Fibroblast-derived VEGF systemically enriches VEGFR1þ cells.
The data in Fig. 1b showed that nude mice bearing Id1-over-
expressing ESCC tumours had elevated serum VEGF that was
host-derived. To determine if this was attributed to increased
VEGF expression in IGF2-activated stromal ﬁbroblasts, sections
of tumour xenografts expressing Id1-overexpressing, Id1-shIGF2,
or vector control were immunostained for mouse VEGF
expression. The results showed obvious increase of VEGF
immunostaining in the stroma of Id1-overexpressing tumours
(Fig. 6a). To conﬁrm that ﬁbroblast-derived VEGF can instigate
VEGFR1þ bone marrow cells, NEFs or IGF2 pre-treated human
NEFs were injected subcutaneously into the ﬂanks of mice, with a
sub-group of mice treated with anti-human VEGF antibody
(Avastin). As showed in Fig. 6b, after 1 week, there were more
VEGFR1þ cells in the bone marrow of mice inoculated with
IGF2-pretreated ﬁbroblasts compared with the control group, and
this effect was abolished by Avastin treatment. Because similar
changes were detected in VEGFR1þ cell population in the lungs
(Fig. 6b), our results also established that activated ﬁbroblasts can
exert their inﬂuence remotely on pre-metastatic niches by
endocrine instigation via ﬁbroblast-secreted VEGF. To investigate
whether ﬁbroblast-derived VEGF could recruit VEGFR1þ cells
to growing tumours, the experiment was repeated using NEFs or
IGF2-pretreated NEFs mixed with ESCC cells (KYSE150) for
establishment of subcutaneous tumour xenografts. After 5 weeks,
we found robust increase in VEGFR1þ cells in the latter group,
whereas treatment with Avastin signiﬁcantly attenuated this
effect. In addition, comparison of tumour size showed that pre-
sence of IGF2-pre-treated ﬁbroblasts could drive tumour growth,
and that Avastin treatment could abolish this effect (Fig. 6c,d). All
these data provide solid evidence to support that stromal VEGF
from ﬁbroblasts drives VEGFR1þ bone marrow cells. Impor-
tantly, our experimental models showed that speciﬁc blockade of
ﬁbroblast-derived VEGF using Avastin was sufﬁcient to suppress
oesophageal tumour growth.
Id1-expressing tumour-primed bone marrow promotes metastasis.
To determine if bone marrow cells primed by the presence of
Id1-expressing tumour can directly facilitate tumour growth by
interacting with cancer cells, bone marrow was collected 2 weeks
after nude mice had been subcutaneously inoculated with
KYSE150 cells expressing Id1, Id1-shIGF2 or vector control, and
then admixed with parental KYSE150 cells for establishment of
subcutaneous tumours in new groups of nude mice (Fig. 7a). This
time point was selected because data from Fig. 5b showed that the
2-week duration was sufﬁcient for the Id1-expressing tumours to
condition the bone marrow and enrich it with VEGFR1þ cells,
and yet the tumours of the three different groups were still of
comparable volume (Fig. 5g) so the tumour size of the ‘donor’
mice would not be a confounding variable in the following
experiments. The bone marrow from mice bearing Id1-expressing
tumour was found to be most potent in enhancing the growth of
the new xenografts; early commencement of VEGFR1 blockade
using MF-1, albeit the lower dose used, was the most effective
in inhibiting tumour growth, resulting in nearly complete
suppression (Fig. 7b).
To study whether the bone marrow cells primed by
Id1-expressing tumour could stimulate ESCC cells to metastasize,
KYSE150-luc cells were mixed with bone marrow cells from the
three groups of ‘donor’ mice, and then injected intravenously into
the tail vein of ‘recipient’ mice (Fig. 7c). We observed that lung
metastasis developed most rapidly in the group injected with
cancer cells mixed with bone marrow donated by mice bearing
Id1-overexpressing tumour xenografts, and that selective
VEGFR1 blockade using MF-1 suppressed lung metastasis
(Fig. 7c). The experiment was repeated using a spontaneous
metastasis model. The results showed that bone marrow cells
primed by Id1-overexpressing tumour in ‘donor’ mice, when
mixed with the EC9706 cells and subcutaneously injected into the
ﬂank of nude mice, had the highest propensity to induce
spontaneous metastasis (two out of ﬁve mice had spontaneous
metastasis in the lungs) compared with the control group (none
of ﬁve mice had spontaneous metastasis in lung) and that MF-1
treatment abolished this effect (no lung metastasis detected in the
group) (Fig. 7d). These data collectively suggest that under the
instigation of Id1-expressing tumours, the VEGFR1þ cells in the
bone marrow were endowed with the capability to stimulate
ESCC cells to proliferate and metastasize even before they were
recruited into primary tumours and secondary sites.
CXCL5/CXCR2 axis contributes to pre-metastatic niche.
Different cells in the pre-metastatic niche may collaboratively
generate a favourable environment for the invasion and
colonization of cancer cells. However, the molecular mechanisms
of pre-metastatic niche remain poorly understood. Our results of
Boyden Chamber assay showed that the conditioned medium of
the lung cell suspension of mice with Id1-overexpressing tumour
xenografts was most effective in attracting the invasion of cancer
cells (Fig. 8a), suggesting that the lungs of these animals
harboured secretory factors that were conducive to colonization
of ESCC cells. A mouse cytokine antibody array was used to
compare the conditioned medium of lung cell suspension pre-
parations from mice bearing Id1-expressing xenografts and that
Figure 5 | Systemic instigation of VEGFR1þ bone marrow cells by Id1-induced IGF2. (a) Illustration within the box shows the experimental scheme for
bone marrow transplantation; lower panel shows representative ﬂuorescence images of recipient control mice without (labelled ‘No’) and with bone
marrow transplantation (labelled ‘Yes’); the red intensity indicated strong GFP signals. (b,c) Quantiﬁcation of VEGFR1þ cells in bone marrow (b) and
lung (c) of mice (female 6–8-week-old nude mice, n¼ 3 per group) from each experimental group by ﬂow cytometry analysis. (d) Representative
three-dimensional tomography image of mice showing accumulation of GFP-positive cells in the thoracic region and in the subcutaneous tumour indicated
by red frames (left panel) and quantiﬁcation of VEGFR1þ cells in the subcutaneous tumours (right panel). (e) Migrating ability of sorted VEGFR1þ and
VEGFR1 bone marrow cells compared by FBS-gradient induced cell migration assay (scale bar, 100mm). (f) The migration ability of VEGFR1þ bone
marrow cells in response to the attraction of conditioned medium from IGF2-induced ﬁbroblasts in the presence or absence of VEGF antibody was
compared (scale bar, 100mm). (g) Outline of experimental scheme and the effect of VEGFR1 blockade on tumour growth (female 6–8-week-old nude mice,
n¼ 6 per group; scale bar, 1 cm). (h) Experimental scheme and bioluminescence imaging showing effect of VEGFR1 blockade on lung metastasis; sections of
lung tissue (H & E stained) are shown in the bottom panel (female 6–8-week old nude mice, n¼ 8 per group; scale bars, 200mm and 100mm for top and
bottom rows of photomicrographs, respectively). Bars, s.d.; *Po0.05; **Po0.01, ***Po0.001 by Student’s t-test.
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from control animals to identify the potential players. There was
increase in macrophage inﬂammatory protein-1 gamma (MIP-
1g) and LPS-induced CXC chemokine (also known as LIX,
CXCL5 or ENA-78) in the Id1-overexpressing group (Fig. 8b).
Since MIP-1g has no identiﬁed human homologue, we focused
our attention on CXCL5. Data from ELISA (Fig. 8c) further
conﬁrmed the elevation of mouse CXCL5 in the lungs of mice
bearing Id1-overexpressing xenografts. Immunohistochemistry
showed that CXCL5 was expressed by alveolar epithelial cells
(Supplementary Fig. 8). We found that recombinant CXCL5
exerted strong chemotactic effect on invasion of ESCC cells
(Fig. 8d). In addition, pre-treatment of lung cell preparations with
anti-CXCL5 neutralizing antibody or blockade of its receptor
CXCR2 on ESCC cells abrogated the enhanced invasion of ESCC
cells attracted by the lung preparations from mice bearing
Id1-expressing tumours (Fig. 8e).
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Figure 6 | Fibroblast-derived VEGF enriches VEGFR1þ cells bone marrow and pre-metastatic sites. (a) Immunohistochemical expression of mouse
VEGF in the tumour xenografts established with KYSE150-Id1, KYSE150-Id1-shIGF2 or vector control cells (scale bar, 20 mm). (b) Flow cytometry data
showing the expression of VEGFR1þ cells in bone marrow (upper panel) and lungs (lower panel) of mice with subcutaneous implantation of indicated
ﬁbroblasts and treatment (female 6–8-week-old nude mice, n¼ 3 per group). (c,d) Flow cytometry analysis of VEGFR1þ cells (c) and comparison of
tumour volume (d) of subcutaneous tumour xenografts established from co-implantation of KYSE150 cells and indicated NEFs in the presence or absence
of Avastin treatment. Photographs show representative tumours of the three groups (female 6–8-week-old nude mice, n¼ 6 per group; scale bar, 1 cm).
Bars, s.d.; *Po0.05; **Po0.01; ***Po0.001 by Student’s t-test.
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Figure 7 | VEGFR1þ bone marrow cells interact with ESCC cells to promote tumour growth and metastasis. (a) Experimental scheme of bone marrow
admixture-tumour xenograft model. Bioluminescence imaging (inset) showed absence of spontaneous metastasis in the lungs 2 weeks after the mice were
subcutaneously injected with Luc-expressing KYSE150-Id1 cancer cells. (b) Representative photos and growth curves of tumours among the experimental
groups (female 6–8-week-old nude mice, n¼6 per group; scale bar, 1 cm). (c) Experimental scheme of the bone marrow admixture-experimental
metastasis model (left panel); bioluminescence imaging and quantiﬁcation of lung metastasis (right panel) (female 6–8-week-old nude mice, n¼ 5 per
group; scale bars, 200mm and 100mm for top and bottom rows of photomicrographs, respectively). (d) Experimental scheme of the bone marrow
admixture-spontaneous metastasis model (left panel); bioluminescence imaging, macroscopic (arrows indicate visible metastases; scale bar, 1 cm) and
microscopic pictures of the dissected lungs and quantiﬁcation of lung weight (right panel) (female 6–8-week-old nude mice, n¼ 5 per group; scale bars,
200mm and 100mm for top and bottom rows of photomicrographs, respectively). Bars, s.d.; *Po0.05; **Po0.01; ***Po0.001 by Student’s t-test.
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Figure 8 | Id1-expressing tumour stimulates the formation of pre-metastatic niches in lungs. (a) Invasion ability of ESCC cells induced by the conditioned
medium of lung cells from mice bearing the tumours expressing Id1 alone, Id1-shIGF2, or vector control, respectively (scale bar, 100mm). (b) Cytokine proﬁling
of conditioned medium of lung cells from nude mice bearing Id1-expressing and control tumour xenograft, respectively, was performed using a mouse cytokine
antibody array. Blue frames indicate the internal positive control and red frames indicate the proteins with markedly increased expression. (c) Quantiﬁcation of
CXCL5 level in conditioned medium of lung cells. (d) The invasion of KYSE270 cells attracted by CXCL5 in the absence or presence of CXCR2 antibody was
determined. (e) The invasion ability of KYSE270 cells attracted by conditioned medium from mouse lung cells in the presence or absence of CXCR2 or CXCL5
antibody was compared. Three biological replicates were performed for in vitro assays. Bars, s.d.; *Po0.05; **Po0.01, ***Po0.001 by Student’s t-test.
Cancer cells
VEGF
VEGFR1+ BM
cells
Lungs
Blood vessel
Primary tumour
Bone marrow
IGF2
Id1
Id1
Id1
Fibroblasts
Figure 9 | Schematic diagram summarizing the regulatory role of the Id1/IGF2/VEGF/VEGFR1 cascade in oesophageal cancer progression. IGF2
secreted by Id1-expressing cancer cells activates ﬁbroblasts to secrete VEGF which exerts paracrine effects in the tumour microenvironment, as well as
instigates VEGFR1þ bone marrow cells in the tumour macroenvironment to facilitate distant metastasis.
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Discussion
Id1 is frequently upregulated in a variety of human cancers
including ESCC17–19. Our previous study showed a positive
correlation between Id1 and IGF2 expressions in ESCC15. In this
study, we showed for the ﬁrst time that IGF2 secreted by
Id1-overexpressing ESCC cells could activate NEFs to secrete
VEGF through the mediation of miR-29c in a p53-dependent
manner. Our in vivo data substantiate that through this
mechanism, Id1-expressing ESCC tumours can indirectly
promote the functional incorporation of VEGFR1þ bone
marrow cells into primary tumours and secondary sites to
facilitate tumour growth and formation of pre-metastatic niche.
Our study demonstrated a novel paradigm of ESCC progression
that involves the orchestration of cancer and non-cancer cells in
the tumour micro- and macroenvironments by the Id1/IGF2/
VEGF/VEGFR1 cascade (Fig. 9).
The roles and mechanisms of ﬁbroblasts in cancer are not fully
understood. As increasing evidence revealed that stromal
ﬁbroblasts can have opposite inﬂuences on tumour develop-
ment4,20,21, there are still intense debates over whether ﬁbroblasts
promote or impede cancer. In addition to stimulating
proliferation, migration and tube-formation of endothelial cells
(Supplementary Figs 2a–c and 3), the IGF2-activated ﬁbroblasts
also promoted tumour malignancy in a multitude of ways
such as enhancing the invasion of oesophageal cancer cells
(Supplementary Fig. 2d) and migration of bone marrow cells
(Fig. 5f) by secreting VEGF. Considering the complexity of the
tumour microenvironment, it is likely that other cell types such
as macrophages and other immune cells may participate in
cancer progression. However, our data clearly demonstrated that
ﬁbroblasts are critical players in a network connecting multiple
cellular components of the tumour microenvironment that evolve
concertedly during cancer progression.
Although the upregulation of VEGF expression by IGF2 had
been reported in hepatocellular carcinoma and keratinocytes22,23,
how IGF2 regulates VEGF in a paracrine manner remains largely
unknown. We have identiﬁed miR-29c as a crucial mediator in
the regulation of VEGF by IGF2 (Fig. 3). The miR-29 family is
reported to be aberrantly expressed in a variety of human
cancers24. MiR-29c, located on chr.1q32.2, is highly conserved
among mammals, thus suggesting its biological importance25.
The known target genes of miR-29c, which have cancer-
promoting functions, include but are not limited to
DNMT3A26, ITGB1 (ref. 27), SIRT1 (ref. 28) and cyclin E29,
some of which have prognostic signiﬁcance in ESCC. Here, our
results showed that p53 regulated miR-29c at transcriptional level
by binding to its promoter, and that IGF2 secreted by ESCC cells
may downregulate p53 by activating AKT/MDM2, thereby
increasing VEGF expression in ﬁbroblasts (Fig. 4). We also
identiﬁed for the ﬁrst time the binding site responsible for
transcriptional regulation of miR-29c by p53. Because p53
mutation is a highly frequent event in ESCC30 whereas
ﬁbroblasts are more genetically stable31,32, this p53-dependent
mechanism may explain why cancer cell-secreted IGF2 secreted
by ESCC cells exerted paracrine rather than autocrine effect to
induce VEGF (Fig. 1b). Taken together, our study has identiﬁed a
crucial regulatory cascade involving IGF2, p53, miR-29c and
VEGF in cancer development.
Oesophageal cancer is the eighth most common cancer
worldwide, and patients with distant metastasis have very poor
survival rate33,34. It is now recognized that metastasis is a very
inefﬁcient event and only less than 1% of disseminated cancer
cells succeed in forming macrometastasis35. It was proposed that
besides genetic changes in the cancer cells, the condition of the
host environment is another equally essential determinant of
cancer progress. Since Lyden et al demonstrated for the ﬁrst time
that impaired recruitment of bone marrow-derived endothelial
and hematopoietic precursor cells can effectively block tumour
angiogenesis and tumour growth36, other bone marrow cells with
tumour-promoting functions, for example CD11bþ /Gr1þ bone
marrow-derived myeloid cells, CXCR6-expressing bone marrow
mesenchymal stem cells and CD13þ myeloid cells, have been
identiﬁed37–39. However, there is also evidence showing that bone
marrow cells may have cancer-suppressive activity40. In our
study, among the various bone marrow cell populations, only
VEGFR1þ bone marrow cells, which have been deﬁned as
hematopoietic progenitor cells that are recruited to distant organs
to create a permissive microenvironment that is conducive to
cancer metastasis36,41, were found to be affected by Id1-induced
IGF2 and could functionally promote tumour growth and
metastasis (Figs 5 and 7). Importantly, our data also showed
that VEGFR1 neutralization could suppress tumour growth and
metastasis driven by Id1.
Increasing attention is being paid to how primary tumour cells
orchestrate the formation of future metastatic sites42,43, but
relatively little is known about what makes the latter receptive to
incoming cancer cells. Id1 was identiﬁed to be an important
mediator of breast cancer metastasis to the lungs44,45.
Interestingly, our own studies with animal models also showed
that Id1 increases the potential of intravenously injected ESCC
cells to colonize the lungs14,46. It was thus exciting to discover
that in addition to increased recruitment of VEGFR1þ BMDCs
(Fig. 5c), there was upregulation of CXCL5 in the lungs of nude
mice xenografted with Id1-expressing ESCC tumours (Fig. 8b).
CXCL5 was ﬁrst identiﬁed as an inﬂammatory peptide with
neutrophil-activating properties47. Subsequently, it was
demonstrated to broadly participate in various cellular
functions associated with cancer development48,49. The
signiﬁcance of CXCL5 in oesophageal cancer has not been
reported. We have provided direct evidence showing that CXCL5
is crucial for the formation of pre-metastatic niches, and that
blockade of the CXCL5/CXCR2 axis can inhibit ESCC cell
invasion. In the lungs, the cellular source of CXCL5 was likely to
be alveolar type II epithelial cells judging from the morphology,
location and scattered distribution of CXCL5-immuno-
stained cells, as in the case of lipopolysaccharide-induced
inﬂammation50.
In conclusion, we have identiﬁed novel elements of a
therapeutically targetable signalling cascade and elucidated
their underlying molecular mechanisms. A full understanding
of the intricacy of cellular interactions and molecular mechanisms
in the tumour micro- and macroenvironment will open
new rational avenues for therapeutic interventions for cancer
patients.
Methods
Cell lines. Human ESCC cell lines KYSE150 and KYSE270 obtained from DSMZ
(Braunschweig, Germany)51, and EC9706 obtained from the Chinese Academy of
Sciences (Shanghai, China)52, were maintained in RPMI 1640 (Sigma, St Louis,
MO, USA) supplemented with 10% fetal bovine serum (FBS) (Invitrogen,
Gaithersburg, MD, USA). The KYSE150 and KYSE270 cell lines were used to
generate stable Id1-overexpressing and vector control cell lines with or without
IGF2 knockdown (designated Id1-shIGF2, Id1-shCON and CON-shCON) using
full length Id1 expression plasmid pBabe-puro-Id1 (kindly provided by Professor
Joan Massague, Memorial Sloan-Kettering Cancer Center, New York, NY, U.S.A)
and pSuper-shIGF2 vector expressing the shRNA against IGF2. A luciferase
expression vector generated by subcloning the luciferase coding region into pLenti/
V5-D-TOPO (Invitrogen) was used to generate the luciferase-expressing stable cell
line KYSE150-Luc and EC9706-Luc cells. The cell lines were authenticated by short
tandem repeat proﬁling, and tested for mycoplasma contamination. The p53 null
mouse embryonic ﬁbroblast cell line (p53 / MEFs), derived from p53 /
mouse embryos, was provided by Professor Randy Y.C. Poon, Hong Kong
University of Science and Technology53. Fibroblasts were maintained in Dulbecco’s
Modiﬁed Eagle Medium (DMEM) (Sigma) supplemented with 10% FBS. Human
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umbilical vein endothelial cells obtained from Invitrogen were cultured in M200
medium supplemented with low serum growth supplement (Invitrogen).
Plasmids. The plasmids expressing p53, that is pcDNA3-ﬂag-p53 (Addgene
plasmids 10838; Addgene, Cambridge, MA, USA)54 and pLenti6/V5-p53 (Addgene
plasmids 22945)55 were gifts from Professor Thomas Roberts (Dana-Farber Cancer
Institute, Boston, MA, USA) and Professor Bernard Futscher (The University
of Arizona, Tucson, AZ, USA), respectively. The p53-knockdown plasmids
pLKO-p53-shRNA-427 and pLKO-p53-shRNA-941 (Addgene plasmids 25636 and
25637)56 were from Professor Todd Waldman (Lombardi Comprehensive Cancer
Center, Washington, DC, USA), with the plasmid expressing scrambled shRNA
(Addgene plasmid 1864)57 from Professor David Sabatini (Massachusetts Institute
of Technology, Cambridge, MA, USA) as control. The BLOCK-iTTM Pol II miR
RNAi Expression Vector Kit with EmGFP (Invitrogen) was used to create the
vectors expressing miR-29c, miR-127-5p and the scrambled miRNA control
(miR-CON). The miR-29c mimics and corresponding negative controls as well as
the miRIDIAN anti-miR-29c inhibitor and the negative control were purchased
from Ambion (Austin, TX, USA). Luciferase reporter plasmid psiCHECK-2
containing wild type 30-UTR sequence of VEGF, designated as psiCHECK-2-
VEGF-30UTR-WT, was kindly provided by Professor Kwanghee Baek (Kyung Hee
University, Korea)58. The ﬁreﬂy luciferase-coding pGL3-basic plasmid containing
the promoter of miR-29c, pGL3-miR29c-pro-WT59, was kindly provided by
Professor Carlos Lo´pez-Otı´n (Universidad de Oviedo, Spain). siRNAs including
human Id1-speciﬁc siRNA (50-TAAACGTGCTGCTCTACGA-30 (ref. 60); human
Id2-speciﬁc siRNA (50-CACGGATATCAGCATCCTG-30), human Id3-speciﬁc
siRNA (50-TCCTACAGCGCGTCATCGA-30)61 and human Id4-speciﬁc siRNA
(50-AGATCCTGCAGCACGTTATCG-30)62 were used to knockdown Id genes.
Human tissue and serum samples. Eleven cases of human ESCC and the
corresponding adjacent normal oesophageal tissues (resected at least 5 cm away
from the tumour lesion) were freshly collected from patients undergoing surgical
resection of primary oesophageal tumour at Queen Mary Hospital, Hong Kong
from 2011 to 2014. None of these patients had received neo-adjuvant
chemotherapy or radiotherapy. Serum samples from 100 ESCC patients (without
prior chemo- or radiotherapy) and 50 healthy individuals were obtained from
Queen Mary Hospital (Hong Kong) and Shantou University Medical College
(Shantou, China). Use of all human samples that were obtained with informed
consent from the patients was approved by the committees for ethical review of
research involving human subjects at the Queen Mary Hospital and Shantou
University.
Isolation of ﬁbroblasts. Cancer-associated ﬁbroblasts (CAFs) and their paired
NEFs were isolated from fresh specimens of primary ESCC tumours and adjacent
non-tumour tissues (resected at least 5 cm away from the tumour lesion) that were
collected from patients who underwent surgical resection at the Queen Mary
Hospital (Hong Kong). Brieﬂy, the tissues were minced into small pieces in sterile
phosphate-buffered saline (PBS) solution and cultured in DMEM supplemented
with 10% FBS. The tissue fragments were incubated for about 14 days and early-
passage (passage 1–3) ﬁbroblasts were cryopreserved for later use. The ﬁbroblasts
used in this study had undergone no more than 10 passages. TP53 mutation status
in NEF3 and NEF4 was determined using the primers listed in Supplementary
Table 4 (ref. 63) and no TP53 mutations were detected in these cell lines.
Drugs and immunoneutralization antibodies. Recombinant human IGF2 and
CXCL5 were from PeproTech (Rocky Hill, NJ, USA). The neutralizing antibodies
against human IGF2 (#AF-292-NA), VEGF (#AF-293-NA) and CXCR2
(#MAB331-100) were purchased from R&D Company (Minneapolis, MN, USA).
Anti-mouse CXCL5 neutralizing antibody (#DS-PB-01247) was from RayBiotech
(Norcross, GA, USA). Rat anti-mouse VEGFR1 monoclonal antibody, MF-1, was
provided by Eli Lilly and Company (New York, NY, USA). Avastin (Bevacizumab)
was purchased from Roche Diagnostics (Mannheim, Germany).
Collection of conditioned media. After the cancer cells or single-cell suspensions
of lungs had been cultured in serum-free medium for 24 h, the conditioned
medium was collected and centrifuged at 1,000 g for 5min. For western blot
analysis, conditioned medium was concentrated about 40-fold using Centricon
Centrifugal ﬁlter (Millipore, Billerica, MA, USA).
Enzyme-linked Immunosorbent Assay (ELISA). Human VEGF ELISA kit (R&D)
and mouse VEGF ELISA kit (RayBiotech) were used to determine the con-
centration of human and mouse VEGF in the serum of experimental animals or
conditioned medium according to the manufacturer’s instructions. Human IGF2
ELISA kit (CusaBio, Wuhan, China) was used to determine the expression of IGF2
in ESCC patients and healthy individuals. Mouse CXCL5 ELISA (RayBiotech) was
used to analyse CXCL5 expression level in the conditioned medium of lung cell
suspensions of nude mice.
Real-time polymerase chain reaction and TaqMan miRNA assay. Total RNA
was isolated using Trizol reagent according to the manufacturer’s protocol
(Invitrogen). miRNA was converted to cDNA using the miScript II RT Kit (Qiagen,
Hilden, Germany), and quantitative PCR (PCR) was performed using the miScript
SYBR Green PCR Kit (Qiagen). The speciﬁc forward primer sequences for each
miRNA are listed in Supplementary Table 3. All the experiments were performed
on MyIQTM2 Real-time PCR Detection System (Bio-Rad, Hercules, CA, USA).
The expression of miR-29c was also quantiﬁed using the TaqMan miRNA Assay
Kit (Applied Biosystems, Carlsbad, CA, USA) according to the manufacturer’s
instructions. Human small nuclear U6 RNA was included as internal control for
miRNA detection.
TaqMan Pri-miRNA assay. TaqMan Pri-miRNA Assay Kit (Applied Biosystems)
was used to quantify primary microRNA of miR-29c (pri-miR-29c). Brieﬂy,
total RNA was isolated from ﬁbroblast cells with Trizol reagent (Invitrogen).
The DNA-free RNA obtained after treating with TURBO DNA-free kit (Ambion,
Foster City, CA, USA) was subjected to TaqMan pri-miRNA assay according to the
manufacturer’s instructions. U6 was used as an internal control.
Western blot analysis. Cell pellets suspended in lysis buffer (Cell Signaling
Technology, Beverly, MA, USA) was centrifuged at 14000 g for 30min at 4 C.
An appropriate amount of protein mixed with protein loading buffer and boiled for
10min at 95 C was then loaded into sodium dodecyl sulfate (SDS) polyacrylamide
gel for electrophoresis. The gel was transferred to polyvinylidene ﬂuoride
membrane. After blocking with 5% fat-free dry milk in Tris-Buffered Saline
Tween-20 (TBST) for 1 h at room temperature, the membrane was probed with
diluted primary antibody for 1–2 h at room temperature, then washed with TBST
and incubated with corresponding horseradish peroxidase-conjugated secondary
antibody for 1 h at room temperature. Signals were detected using ECL Plus
Western blotting detection system (Amersham, Piscataway, NJ, USA) and observed
by BioMax Light Film (Kodak, Rochester, NY, USA). The primary antibodies
used included VEGF (#sc-152; 1:500 dilution), Id1 (#sc-488; 1:1000 dilution),
Id2 (#sc-489; 1:1000 dilution), Id3 (#sc-490; 1:1000 dilution), Id4 (#sc-13047;
1:1000 dilution), PIGF (#sc-1880; 1:1000 dilution, FGF (sc-79; 1:1000 dilution) and
actin (#sc-1616; 1:2000 dilution) from Santa Cruz Biotechnology; phospho-MDM2
(#3521; 1:1000 dilution), phospho-AKT (#9271; 1:500 dilution) AKT (#4691;
1:1000 dilution), p53 (#2524; 1:2000 dilution) from Cell Signaling Technology;
IGF2 (#AF-292-NA;1:500 dilution) and CXCL5 (#DS-PB-01247; 1:1000 dilution)
from RayBiotech; and a-SMA (#A5228; 1:1000 dilution; Sigma). Full blots of all
western blots are presented in Supplementary Figs 9–12.
Cell proliferation assay. Cell viability was measured using 3-(4, 5-Dimethyl
thiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. Brieﬂy, cells were
seeded in 96-well plates and incubated with desired medium. At the end of
experiment, 20ml of MTT reagent (5mgml 1 in PBS) (Sigma) was added and the
cells were incubated for 4 h at 37 C, followed by adding 200 ml DMSO. Absorbance
at 570 nm was measured using spectrophotometer.
In vitro cell migration and invasion assay. The motility of cells in response to a
chemoattractant was investigated using migration chamber assay (Millipore). The
cells of interest were loaded into the upper compartment of the chamber and the
chemoattractant as indicated was added to the lower chamber. Following an
incubation period of 24 h, the migrated cells were ﬁxed with methanol and stained
with crystal violet (0.2%), and then quantiﬁed under the microscope in six random
ﬁelds. BioCoat matrigel invasion chambers (BD Biosciences, San Jose, CA, USA)
were used to investigate the invasion of ESCC cells attracted by conditioned
medium of ﬁbroblasts. The invaded cells were ﬁxed and stained with crystal violet,
and then quantiﬁed by submerging the chambers in 1% SDS buffer and measuring
the absorbance of the solution at 570 nm.
Endothelial tube formation assay. Human umbilical vein endothelial cells were
seeded in a 96-well plate, which was pre-coated with matrigel (BD Biosciences) and
fed with different medium as indicated. After 6 h, capillary-like tubes were imaged
and the extent of tube formation was quantiﬁed by measuring the total tube
length in six random ﬁelds from each well using the software Stereo Investigator
(MBF Bioscience, VT, USA).
Immunoﬂuorescence staining. Fibroblasts or cancer cells seeded on the
pre-coated coverslips were ﬁxed with 4% paraformaldehyde for 10min and then
permeabilized in Triton X-100 solution (0.1%) at room temperature for 30min.
After blocking with 3% BSA for 30min, cells were incubated with the primary
antibodies against ﬁbronectin (#610077; BD Biosciences) and E-cadherin
(#610181; BD Biosciences) at 4 C overnight. After incubating with ﬂuorochrome-
conjugated secondary antibody followed by counterstaining with 40 ,6-diamidino-2-
phenylindole (DAPI), the slides were mounted in ﬂuorescence mounting medium
(DAKO Diagnostics, Mississauga, ON, USA) and the images were captured under a
ﬂuorescent microscope.
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Immunohistochemical staining. Parafﬁn-embedded sections were deparafﬁnized,
rehydrated and then incubated with 0.3% hydrogen peroxide for 30min. Antigen
retrieval was performed in 0.1M citrate buffer (pH 6.0) for 15min. After blocking
with normal serum followed by incubation with primary antibody, corresponding
biotinylated secondary antibody was applied. Peroxidase-conjugated avidin-biotin
complex and 3, 30-diaminobenzidine (DAKO) were used as chromogen, and the
sections were counterstained with hematoxylin and eosin (H & E). Microvessel
density was calculated as the mean number of CD31-positive vessels in six random
ﬁelds from representative tumour sections. The CD31 primary antibody (#sc-1506;
1:100 dilution) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA,
USA). The CXCL5 (#orb13450; 1:100 dilution) and anti-mouse VEGF antibody
(#orb303953; 1:50 dilution) was purchased from Biorbyt Ltd. (Cambridge,
Cambridgeshire, UK).
Flow cytometry analysis and cell sorting. Cell suspensions were labelled with
anti-mouse phycoerythrin (PE)-conjugated VEGFR1 (#FAB4711P; R&D Systems),
anti-mouse PE-F4/80 (#12-4801; eBioscience Inc., CA, USA), anti-mouse
PE-VEGFR2 (#12-5821; eBioscience), anti-mouse PE-CD335 (#12-3351;
eBioscience), anti-mouse PE-CD202b (TIE2) (#12-3351; eBioscience), anti-mouse
PE-Ly-6G (Gr-1) (#12-5931; eBioscience) and anti-mouse allophycocyanin
(APC)-conjugated Cd11b (#53-0112; eBioscience) with corresponding isotype
control. Then the samples were analysed on BD FACSCanto II Analyzer
(BD Biosciences), and cell sorting was performed on BD FACSAria I Cell Sorter
(BD Biosciences). The data analysis was carried out by using FlowJo software
(Tree Star Inc., Ashland, OR, USA).
Prediction of miRNA binding sites on 30UTR of VEGF. Three software
programs including TargetScan (http://www.targetscan.org/vert_50/)64,
miRanda (http://www.microrna.org/microrna/getExpr Form.do)65 and PicTar
(http://pictar.mdc-berlin.de/cgi-bin/PicTar_vertebrate.cgi)66 were used to predict
the putative binding sites on the 30UTR of VEGF for miRNAs.
Site-directed mutagenesis and luciferase assay. QuikChange Lightning
Site-directed Mutagenesis Kit (Agilent Technologies, Santa Clara, CA, USA)
was used to generate mutant constructs for psiCHECK-2-VEGF-30UTR and
pGL3-miR29c-pro. The primers used for generating psiCHECK-2-VEGF-30
UTR-mut were: forward (50-ttttaatatttgttatcatttatttattgggggtactgtttatccgtaataattgt
ggggaaa-30) and reverse (50-tttccccacaattattacggataaacagtacccccaataaataaatgataaca
aatattaaaa-30). The primers used for generating pGL3-miR29c-pro-mut are listed in
Supplementary Table 5. Luciferase activity was measured by using Dual-Luciferase
reporter assay according to the manufacturer’s instructions (Promega, Madison,
WI, USA).
Chromatin immunoprecipitation-quantitative PCR. Two transcription
factor binding site prediction software programs ConTra V2 (ref. 67) and TRRD68
were used to identify the potential p53 binding sites in the promoter region of
miR-29c. The chromatin immunoprecipitation (ChIP) assay was performed by
using simple CHIP enzymatic chromatin IP kit (Cell Signaling, Beverly, MA, USA)
according to the manufacturer’s manual. In brief, the in vivo protein and DNA
crosslinking was performed using 37% formaldehyde, followed by sonication and
chromatin digestion. The protein–DNA complexes were immunoprecipitated using
p53 antibody or negative control IgG antibody. After elution and reversal of
crosslinking with proteinase K, the puriﬁed DNA was subjected to SYBR Green
PCR analysis (Bio-Rad). Relative mRNA expression was calculated using the
comparative Ct method after normalization to GAPDH control. The primers used
in this protocol were listed in Supplementary Table 6.
Preparation of mouse bone marrow and tissue suspensions. All animal
care and experimental procedures described in this paragraph and subsequent
paragraphs were approved by the Committee on the Use of Live Animals in
Teaching and Research, University of Hong Kong, or Jinan University. All animals
were sex- and age-matched in the animal experiments, and littermates were used.
The investigators were not blinded to the experimental groups. Bone marrow was
collected by ﬂushing the tibias and femurs with sterile DMEM: Nutrient Mixture
F-12 (DMEM/F-12) (Invitrogen). The mixture was passed through an 18-gauge
needle and ﬁltered through 70-mm nylon mesh cell strainer to dissociate the cells.
The tumour xenografts and lungs harvested from mice were minced to 1mm3 size
and digested in collagenase (100 mgml 1) for 20min at 37 C with continuous
shaking. The sorted VEGFR1þ bone marrow cells and lung cells were ex vivo
expanded in DMEM/F12 medium.
Bone marrow transplantation. Nude mice (recipient mice) were placed on
acidiﬁed drinking water (pH 2.5–3.0) for 2 weeks before irradiation. They were
exposed to 600 rads of gamma irradiation from Caesium-137 source (MDS
Nordion Gammacell 3000 Elan II, Best Theratronics Ltd, Ottawa, Ontario,
Canada). Eight to ten hours later, about 2 106 bone marrow cells harvested
from GFP-expressing donor mice (C57/FVB-GFP) and re-suspended in 100 ml
sterile PBS were injected into the tail vein of the recipient mice. Successful
engraftment of bone marrow was veriﬁed by GFP ﬂuorescence detection using
Maestro 2 in vivo imaging system (Cambridge Research & Instrumentation, Inc.
Woburn, MA, USA).
Tumour xenograft experiment. In brief, 1 106 KYSE150 cells alone or 5 105
KYSE150 cells admixed with 5 105 bone marrow cells were re-suspended in equal
volumes of PBS and matrigel (total volume of 100 ml) and subcutaneously injected
into the ﬂanks of mice to establish tumour xenografts. Sub-groups of mice
were treated with indicated doses of MF-1 intraperitoneally thrice weekly. For
xenografting of ﬁbroblasts alone, 1 106 normal oesophageal ﬁbroblasts (NEF3) or
IGF2-pretreated NEF3 suspended in equal volumes of PBS and matrigel were
subcutaneously injected into the ﬂanks of mice. In another experiment, 1 106
NEF3 cells or IGF2 pre-treated NEF3 were admixed with 1 106 KYSE150 cells to
establish subcutaneous tumour xenografts. Sub-groups of mice were treated with
Avastin (5mg kg 1) intraperitoneally thrice weekly when the tumour xenografts
reached 5mm in diameter. During the experiment, the tumour volume was
measured every 3 days. Tumour volumes were calculated with the equation
V¼ (lengthwidth2)/2.
Experimental metastasis model. Brieﬂy, 1 106 luciferase-expressing
KYSE150-luc cells or 5 105 KYSE150-luc cells admixed with 5 105 bone
marrow cells were injected intravenously into the animals via the tail vein.
Sub-groups of mice were treated with indicated doses of MF-1 intraperitoneally
thrice weekly. Isotype IgG was given to the control group. Metastasis was
monitored weekly by bioluminescent imaging (Xenogen IVIS 100 in vivo imaging
system, PerkinElmer, Hopkinton, MA, USA).
Spontaneous metastasis model. The ESCC cell line EC9706, which is capable
of forming spontaneous lung metastasis after subcutaneous implantation in
nude mice69, was used to generate primary tumours. Brieﬂy, 2 106 EC9706-luc
cells admixed with 2 106 bone marrow cells were inoculated subcutaneously
into the ﬂank of nude mice. Sub-groups of mice were treated with indicated
doses of MF-1 intraperitoneally thrice weekly with isotype IgG as control.
Metastasis was monitored by bioluminescent imaging. At the end of the
experiment, the lungs were dissected, weighed and examined histologically for
presence of metastases.
Mouse cytokine antibody array. Single-cell suspensions of lung were cultured in
serum-free medium for 24 h and then the culture medium was collected. A mouse
Cytokine Antibody Array containing 62 mouse cytokines (#AAM-CYT-3;
RayBiotech) was utilized to detect cytokines that were differentially secreted in the
lungs of mice bearing Id1-expressing tumour xenografts.
Gene expression and survival data from patient datasets. Gene expression
datasets from patients with breast cancer (GSE 9014) was downloaded from the
National Center for Biotechnology Information Gene Expression Omnibus (GEO).
R scripting was used to extract the expression values of genes of interests and
clinical data from the data matrices. Gene expressions were further divided
into high and low levels using median expression level as the cut-off value for
Kaplan–Meier survival analyses.
Statistical analysis. All in vitro experiments and assays were repeated at least
three times. The data were expressed as mean±s.d. and compared by Student’s
t-test or ANOVA. Animal sample size for each study was chosen on the basis of
literature documentation of similar well-characterized experiments, and no
statistical method was used to predetermine sample size. Survival analysis
was performed by Kaplan–Meier method with the log-rank test, using the
Statistical Package for the Social Sciences (SPSS) (SPSS Inc, Chicago, IL).
The expression level of miR-29c in NEF and matched CAF was compared using
paired t-test. The expression levels of serum IGF2 and serum VEGF were compared
using unpaired t-test. Correlations between Id1 and VEGF, VEGF and IGF2,
a-SMA and IGF2, miR-29c and IGF2 were assessed using Pearson’s rank
correlation coefﬁcient (two-tailed). Univariate and multivariate survival
analyses were performed using the Cox proportional hazard model with
a forward stepwise procedure (the entry and removal probabilities were 0.05
and 0.10, respectively). P valueso0.05 were considered as signiﬁcant for all
experiments.
Data availability. The gene expression datasets from patients with breast cancer
referenced in this study (GSE 9014) were downloaded from the National Center for
Biotechnology Information Gene Expression Omnibus (GEO). All other data are
available within this manuscript and its supplementary information or from the
corresponding author upon reasonable request.
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